EMTRICITABINE
Synonyms. Emtricitabine; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-FTC; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; Coviracil; Emtriva; FTC; dOTFC;

EMTRICITABINE
 

PRODUCT IDENTIFICATION

CAS RN

 143491-57-0

EINECS RN

  

FORMULA

 C8H10FN3O3S

MOLE WEIGHT

 247.25

H.S CODE

  

SMILES

 S1C[C@H](O[C@H]1CO)n1cc(c(nc1=O)N)F

CLASSIFICATION

Anti-Infective, Antiretroviral, Antiviral, Deoxycytidine nucleoside analog, Pyrimidone, Oxathiolane, Organofluoride

EXTRA NOTES

Antiviral [treatment of HIV-1 and hepatitis B infections]
A nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection 

 

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE.

white to off-white crystalline powder

MELTING POINT

219 - 220 C

BOILING POINT

 440 C

DENSITY

1.82

SOLUBILITY IN WATER

 
SOLVENT SOLUBILITY  

VAPOR DENSITY

 

log P(octanol-water)

  

VAPOR PRESSURE

  

AUTOIGNITION TEMP

  
pH

 

REFRACTIVE INDEX

 

FLASH POINT

221 C

 
STABILITY AND REACTIVITY
STABILITY Stable under normal conditions.

INCOMPATIBLE MATERIALS

Oxidizing agents
POLYMERIZATION

Has not been reported

NFPA RATINGS

 

 

EXTERNAL LINKS & GENERAL DESCRIPTION

Wikipedia Linking

Google Scholar Search

Drug Information Portal (U.S. National Library of Medicine) - Emtricitabine

PubChem Compound Summary - Emtricitabine

Drug Bank - Emtricitabine

KEGG (Kyoto Encyclopedia of Genes and Genomes) -  Emtricitabine

http://www.ebi.ac.uk/chebi/ -  Emtricitabine

http://www.ncbi.nlm.nih.gov/ - Emtricitabine

http://hivinsite.ucsf.edu/
Emtricitabine was approved by the FDA in July 2003 for use in combination with other antiretroviral agents in adults with HIV infection. In 2005, it was approved for use in pediatric patients. Initial approval was based on the results of 2 Phase III clinical trials. A double-blind study compared emtricitabine + didanosine + efavirenz with stavudine + didanosine + efavirenz as initial treatment in individuals who had not previously received antiretroviral therapy. At 24 and 48 weeks, patients receiving emtricitabine had significantly higher rates of virologic suppression than did stavudine recipients. An open-label trial of treatment-experienced patients with HIV RNA <400 copies/mL on a lamivudine-containing regimen randomized patients either to continue lamivudine or to switch to once-daily emtricitabine, in combination with either stavudine or zidovudine and either a protease inhibitor or an NNRTI. The proportion of patients whose viral loads remained suppressed at the <400 copies/mL and <50 copies/mL level were similar in the two treatment groups.

https://www.factsandcomparisons.com/
Emtricitabine is a deoxycytidine analog nucleoside reverse transcriptase inhibitor that is indicated for the treatment of HIV infection given with other antiretroviral agents and appears safe and effective. Unlike some of the other antiviral agents, emtricitabine is unlikely to be associated with drug interactions. It joins a growing group of agents that offer dosing advantages in HIV therapy with once-daily dosing and low pill burden.

 

 

SALES SPECIFICATION

APPEARANCE

white crystalline powder

ASSAY

99.0% min

SPECIFIC ROTATION

-138° ~ -143°
RESIDUE IGNITION

0.01% max
LOSS ON DRYING

0.1% max
MELTING POINT

219 - 220 C

 

TRANSPORT & REGULATORY INFORMATION

UN NO.

Not regulated

HAZARD SYMBOL

  
PACKING GROUP  

 

SAFETY INFORMATION

HAZARD OVERVIEW

Not known

GHS

  

SIGNAL WORD

 

PICTOGRAMS

 

HAZARD STATEMENTS

 

P STATEMENTS

 
EC DIRECTIVES

 
HAZARD CODES

 

RISK PHRASES

  

SAFETY PHRASES

  

 

PACKING

 

 

PRICE INFORMATION